Market Size of Sustained Release Excipients Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 7.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sustained Release Excipients Market Analysis
The sustained release excipients market is anticipated to register a CAGR of 7.1% during the forecast period.
The COVID-19 pandemic had an adverse effect on the market. Potential shortages as a result of export bans from India and China, the major suppliers of API and generics, have prompted governments in many countries to consider supply chain self-sufficiency and issue regulations to prevent shortages in such a crisis. In this regard, the European Commission published a new guideline on foreign direct investment and the free movement of capital from third-world countries in March 2020, stating that foreign investments in the European Union (EU), particularly those affecting the health market, must be subjected to risk assessments to avoid any negative impact on the European Union's capacity to meet the health demands of its citizens. The uncertainty that surrounded COVID-19 highlighted the challenges of maintaining a global drug supply chain. With the reopening of the markets globally, the market studied is gaining traction again.
The market is growing due to the initiatives such as product launches by key market players. For instance, in March 2022, Athena Bioscience LLC launched Nexiclon XR, the only once-daily clonidine extended-release tablet indicated for the treatment of hypertension. Athena acquired exclusive rights to commercialize the product from Tris Pharma Inc. in February 2021. Similarly, in July 2022, Dr. Reddy's Laboratories Ltd launched Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets, a generic therapeutic equivalent to Toviaz (fesoterodine fumarate) in the US market following the approval by the USFDA. These initiatives are expected to increase the growth of the market during the forecast period.
Factors for the growth of the market include the increased benefits over conventional dosage forms and antibiotic resistance. One of the major challenges for marketers of pharmaceutical products is the compliance of the patient. When a drug needs to be administered several times a day, patients' acceptance of the medication can decrease considerably, leaving the risk of poor treatment. In this case, a standard solution to increase medication acceptance is to formulate the drug in a dosage form that steadily releases the active ingredient over an extended period. Sustained-release profiles allow tailored dosing of the active ingredient over an extended period of up to 24 hours. Common ways to achieve such release rates are the use of film coating, a sustained-release matrix, or sustained-release drug-loaded granules.
Such sustained-release formulations have gained considerable traction in the pharmaceutical industry and are expected to continue to be a significant tool to improve the patient's experience with existing and new drugs. It also represents an attractive opportunity for companies and formulators to differentiate their potentially generic product from standard instant-release versions in the market.
